Q2 2026 Humacyte Inc Earnings Call Transcript
Key Points
- Humacyte Inc (HUMA) reported highly statistically significant positive interim results from its VO12 Phase III trial, showing the ATEV provided 91 more catheter-free days than the standard-of-care AV fistula in female dialysis patients (p=0.0007).
- The company is advancing its pipeline with FDA acceptance of an IND for a first-in-human study of its coronary tissue-engineered vessel (CTAV) in CABG, with the study expected to begin in the current quarter.
- Humacyte Inc (HUMA) has strengthened its commercial team with experienced leadership, including a new Chief Commercial Officer and Chief Surgical Officer, and is seeing early signs of adoption and increased utilization among influential hospitals.
- The company is preparing for a supplemental BLA submission for dialysis access in the second half of 2026, with a target filing in November and potential priority review, which could lead to a launch as early as mid-2027.
- Humacyte Inc (HUMA) has secured dedicated U.S. Department of Defense funding to support the evaluation and incorporation of its vascular repair technology for warfighters, enhancing its military market potential.
- Humacyte Inc (HUMA) reported very low commercial sales of only $0.4 million in Q2 2026, reflecting a rebuilding quarter and slower-than-expected uptake in the vascular injury indication.
- The company recorded a $0.7 million inventory reserve in Q2 and $2.3 million for the six months, along with expenses related to unused production capacity, indicating inefficiencies in manufacturing.
- Humacyte Inc (HUMA) continues to incur significant net losses, with a net loss of $36.8 million in Q2 2026 and $54.4 million for the first half, driven by non-cash remeasurement of contingent liabilities.
- The commercial team underwent a complete rebuild, which disrupted momentum and delayed tangible results, with management acknowledging that the impact of new strategies will only be visible in the second half of 2026.
- The company faces uncertainty regarding FDA review timelines and label negotiations for the dialysis indication, with potential delays if priority review is not granted, pushing launch to later in 2027.
Good morning, ladies and gentlemen, and welcome to HumanSight's second quarter 2026 earnings conference call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded. I will now turn the call over to Tom Johnson with LifeSci Advisors. Please go ahead.
Thank you, operator. Before we begin with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal securities laws.
These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.
Forward-looking statements made during this call speak only as the date hereof and the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
